Navigation Links
Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA
Date:2/4/2008

EMEA).

One-year findings from one of two ustekinumab Phase 3 trials were presented for the first time at the annual meeting of the American Academy of Dermatology this past Saturday, February 2.

About Psoriasis

Psoriasis is a chronic, immune-mediated disease, which results from the overproduction of skin cells resulting in their accumulation on the surface of the skin, which causes red, scaly plaques that may itch and bleed. It is estimated that 125 million people worldwide have psoriasis, including two percent of both the U.S. and European populations, or some 7.5 million Americans and 10 million Europeans. Nearly one-quarter of people with psoriasis have cases that are considered moderate to severe.(1)

About Ustekinumab

Ustekinumab is a new, human monoclonal antibody in Phase 3 development by Centocor, Inc. for the treatment of moderate to severe plaque psoriasis, and is being investigated as an infrequently administered subcutaneous injection. Ustekinumab is a novel biologic therapy that targets interleukin 12 (IL-12) and interleukin 23 (IL-23), naturally occurring proteins that are important in regulating the immune system and that are also believed to play a role in immune-mediated inflammatory disorders.

Centocor discovered ustekinumab and has exclusive marketing rights to the product in the United States. Janssen-Cilag companies have exclusive marketing rights in all countries outside of the United States.

About Centocor, Inc.

Centocor is harnessing the power of world-leading research and biomanufacturing to deliver innovative biomedicines that transform patients' lives. Centocor has already brought innovation to the treatment of Crohn's disease, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, ulcerative colitis, pediatric Crohn's disease and psoriasis.

The world leader in monoclonal antibody production and technology, Centocor has brought critical biologic therapies to patients
'/>"/>

SOURCE Centocor, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Medarex Announces Extension of Broad Antibody Development Relationship with Centocor
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
4. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
5. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
6. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
7. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... UK (PRWEB) , ... July 27, 2015 , ... Production ... growth over the past few years in the EU. For instance, it surpassed the ... the EUR 92 million mark in 2010. Germany is a major producer, while Italy ...
(Date:7/27/2015)...   Inocucor Technologies Inc ., the agriculture ... farmers, has received a notice of allowance from ... patent application to protect Inocucor consortia and unique ... yields on farms and in greenhouses. ... microbial consortium and its fermentation byproducts, which are ...
(Date:7/27/2015)... ... 27, 2015 , ... BlueInGreen® announced the addition of EnviroSales ... the world’s most efficient gas dissolution technology to all of Florida, excluding the ... industrial and municipal markets. With offices located in Sarasota, Sebring and Melbourne Beach, ...
(Date:7/27/2015)... , July 27, 2015 The ... announced the winners of its annual Klerman and ... by scientists who have been supported by NARSAD ... scientists to pursue innovative ideas in neurobiological and ... of concept for the early detection, treatment, prevention ...
Breaking Biology Technology:High Tenacity Filament Yarn of Viscose Rayon Consumption to Grow Swiftly in the EU, Forecasts BAC Reports in New Study Available at MarketPublishers.com 2Inocucor Technologies Receives Groundbreaking U.S. Patent for Proprietary Biological Processes that Stimulate Plant Growth 2Inocucor Technologies Receives Groundbreaking U.S. Patent for Proprietary Biological Processes that Stimulate Plant Growth 3BlueInGreen Brings Water Treatment Technology to Florida 2Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 2Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 3Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 4Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 5Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 6
... Advocacy Groups Launch Joint Effort to Preserve Eyesight of,Millions At-Risk ... that eye exams are being,ignored by many aged over 40. ... the last year to have their eyes checked, even though,twice ... or early,death. The survey showed that awareness of glaucoma was ...
... CRVL ), a leading provider of workers, ... 150,000 facility and,provider locations to its national CorCare ... provider network additions are the,result of a new ... Petersburg, FL. With more than 5,500 hospitals ...
... Time-Saving, ATLANTA, Oct. 1 Harmonex ... a revolutionary software platform,designed to assess children, ... CliniCom(TM), an intuitive, computer assisted intake and ... settings, gathers information,directly from patients and their ...
Cached Biology Technology:International Survey Shows People Over Forty Ignore Risk of Blindness 2International Survey Shows People Over Forty Ignore Risk of Blindness 3International Survey Shows People Over Forty Ignore Risk of Blindness 4International Survey Shows People Over Forty Ignore Risk of Blindness 5CorVel Corporation Medical Provider Network Adds New Providers to Increase Savings and Improve Access to Care 2CorVel Corporation Medical Provider Network Adds New Providers to Increase Savings and Improve Access to Care 3Harmonex Introduces CliniCom(TM), a Breakthrough in Psychiatric Intake and Assessment Technology 2Harmonex Introduces CliniCom(TM), a Breakthrough in Psychiatric Intake and Assessment Technology 3
(Date:7/9/2015)... Calif. , July 9, 2015  Synaptics Inc. (NASDAQ: ... solutions, announced today that it will report financial results ... Thursday, July 30, 2015 after the close of market. ... analysts and investors at 2:00 p.m. PT (5:00 p.m. ... To participate on the live call, analysts ...
(Date:7/9/2015)... , July 9, 2015  Synaptics Inc. ... of human interface solutions, today announced a ... first fully hardware encapsulated fingerprint sensor and ... technology is literally off the grid, isolating ... matching within the fingerprint sensor to provide ...
(Date:7/8/2015)... DIEGO , July 8, 2015  Trovagene, ... cell-free molecular diagnostics, today announced the launch of ... the Company,s Precision Cancer Monitoring℠ (PCM) technology for ... receiving one or a combination of the novel ... Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient study ...
Breaking Biology News(10 mins):Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
... a prevalent fungal pathogen that causes 10,000 deaths per ... antifungal drugs by duplicating a section of one of ... yeast present in 80 percent of humans, is usually ... oral and vaginal infections (candiasis or thrush) that are ...
... at the Stanford University School of Medicine have taken ... cells that could eventually be transplanted into living organisms. ... surgical resident Oscar Abilez, MD, and colleagues have successfully ... building blocks of blood vessels, after placing them in ...
... technique of distraction has been researched and successfully applied ... with certain medical procedures. The use of distraction is ... psychological element in the perception of pain, with the ... the perception of the pain. , Distraction techniques ...
Cached Biology News:U of M researchers discover genetic key to treating deadly fungal infections 2Stanford doctors advance in bid to turn mice stem cells into blood vessels 2Stanford doctors advance in bid to turn mice stem cells into blood vessels 3Virtual realities against pain 2
Sphingosine 1-phosphate receptor Edg-1...
Bag-1 (K-20)...
... atoms at the 3, 3', 4, and ... as an internal standard for the quantification ... LC-mass spectrometry. PGE2 is one of the ... one of the most widely investigated prostaglandins. ...
, Glycerol 30%...
Biology Products: